VANCOUVER, Washington — March 5, 2026 — Leads & Copy — CytoDyn Inc. (OTCQB: CYDY) has finalized a $17.5 million financing round, with Paulson Investment Company acting as placement agent.
The clinical-stage oncology company, which is advancing leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor, said the financing will support the continued advancement of its clinical programs and strategic priorities.
CytoDyn is exploring potential roles for leronlimab in immuno-oncology, including indications such as triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC).
Robert E. Hoffman, CFO of CytoDyn, said the completion of the financing in a challenging capital markets environment reflects investor support for the company’s clinical strategy. He added that the financing strengthens the company’s balance sheet and is expected to fund current operations into 2027.
Net proceeds from the financing will primarily support ongoing and planned trials, regulatory engagement, and data analysis. The company said additional funds may be allocated toward manufacturing readiness, regulatory and compliance infrastructure, and general working capital.
CytoDyn is dedicated to advancing leronlimab, which it describes as a first-in-class humanized monoclonal antibody that targets the CCR5 receptor. The company says the CCR5 receptor is a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders.
More information on the fundraising activities is available in CytoDyn’s filings with the Securities and Exchange Commission, including its Current Report on Form 8-K filed on March 5, 2026.
CytoDyn says it is guided by a mission to improve patients’ quality of life through therapeutic innovation and is committed to integrity, responsibility, and service as it works to bring treatments to patients worldwide.
Source: CytoDyn
